 | Switzerland, 07.2012,
Rontis AG announces the first stage of patient enrollment in the prospective, multicenter eazy Registry evaluating the safety and performance of Zeus CCTM, Peripheral Balloon-Expandable CoCr Stent System.
download the newsletter |
| |
 | AbraxTM CE approval
Switzerland - 06.2012 - Advancing the treatment of Coronary Artery Disease, Rontis AG announces CE approval of the AbraxTM Sirolimus-Eluting Biodegradable Polymer Stent System.
The new medical device complements Rontis AG Drug-Eluting Stent series. AbraxTM CE approval was supported by the 2-year results from the AbraxTM study.
AbraxTM leverages the biodegradable polymer technology with the immunosuppressant action of Sirolimus. Additionally, the carbonization procedure of the stent platform increases the biocompatibility and bioactivity of AbraxTM. It is available in a wide range of entire size matrix from 2.0-4.0 mm in diameter and 10-38 mm in length. |
| |
 | May 15-18, 2012
Rontis has successfully participated for the 10th consecutive time in the Euro PCR 2012 in Paris, from the 15th up to the 18th of May 2012.
photo album |
| |
 | May 4-5, 2012
We have successfully participated in the TCT Mediterranean at 4-5 May, 2012 in Limassol, Cyprus.
visit site |
| |
 | Rontis announces the launch of Zeus SXTM Registry
A European multi-center, prospective, non-randomized post market surveillance registry designed to document the clinical performance of the Zeus SXTM Peripheral Nitinol Self-Expanding Stent System in routine clinical practice.
download the registry announcement |
| |
 | February 9-11 2012
We have successfully participated in the Joint Interventional Meeting at 9-11 February, 2012 in Rome
visit site |
| |
 | January 12-14 2012
We have successfully participated in the IROS 2012, 12-14 January, Salzburg, Austria
visit site |
| |
 | November 25-26 2011
We have successfully participated in the XVIII National Congress of the Cardiology Society of Serbia, 25-26th November, Belgrade, Serbia
visit site |
| |
 | November 16-19 2011
We have successfully participated in Medica, 16th to 19th of November 2011, in Dusseldorf, Germany.
visit site |
| |
 | November 7-11 2011
We have successfully participated in TCT 2011, 7th to 11th of November 2011, in the Moscone Center in San Francisco CA, USA.
visit site |
| |
 | September 10-14 2011
We have successfully participated in CIRSE 2011, 10th to 14th of September 2011, in Munich, Germany.
visit site |
| |
| Rontis announces the launch of EAZY Registry
A prospective multicenter registry to evaluate the safety and performance of the balloon-expandable
ZEUS CC TM stent in patients with iliac obstructive disease.
download the study announcementdownload the study synopsis protocolConnect to the EAZY registry official website |
| |
 | Rontis launches "Rontis Interventional" App
Rontis Interventional is an angioplasty procedure education tool designed to help interventionalists to explain this procedure to their patients and also learn about the products Rontis offers. This new App includes a video of the angioplasty procedure and interactive parts showing the guidewires, balloon catheters and stents of Rontis' portfolio providing information about technical specifications, as well. Pictures of each product and documents concerning them such as clinical trials and studies are also provided.
download the application |
| |
 | Interview (May 18th, 2011) of Rontis Product Development Director, Mr. Arsen Semertzioglou.
In this 3.28 minute interview, Mr. Semertzioglou is briefly outlining the activities and strategy of Rontis, explains key features of our portfolio and presents the forthcoming products.
visit site |
| |
 | June 14-17 2011
We will participate in 13th National Congress on Cardiovascular Update, 14-17 June 2011, Razi Conference Hall, Tehran, Iran.
visit site |
| |
 | May, 2011 - Rontis announces the launch of Zeus SXTM Self-Expandable Stent System for peripheral applications
The new Zeus SX TM is designed to offer optimal combination of flexibility, pushability and radial force providing ergonomic handle for accurate and controlled deployment, as well. It has nitinol, closed cell stent design and low strut thickness. The 8 tantalum radiopaque markers along with the radiovisible sheath and soft tip provide excellent visibility for accurate release and better target location. Its braided sheath has 4 zones of flexibility for better support. The product has a unique handle system optimized for single-handed operation. |
| |
 | May, 2011 - Rontis announces the launch of Triton BTKTM, Below-The-Knee Balloon Dilatation Catheter up to 210 mm long
Triton BTK TM Balloon Dilatation Catheter is designed to feature the unique aspects surrounding the anatomy oand physiology of below-the-knee vessels such as smaller vessel diameter and the more sluggish flow pattern. It has a short, flexible and tapered 0.016" tip engineered to promote easier navigation and 0.021" crossing profile that allows trackability to the most challenging lesions. The product has balloon diameters from 2 to 5 mm and balloon lengths from 90 to 210 mm. |
| |
 | May 17-20, 2011
We have successfully participated in 9th consecutive time in the Euro PCR in Paris, from the 17th up to the 20th of May 2011. Visit our booth P02, Level 1, Hall, Paris
visit site |
| |
 | January 24-27, 2011
We have successfully participated in Arab Health, 24th and 27th of January 2011, Dubai, United Arab Emirates.
visit site |
| |
 | January 19-21, 2011
We have successfully participated in LINC (Leipzig Interventional Course), January 19th - 21st, Leipzig, Germany
visit site |
| |
| November 17-20, 2010
We have successfully participated in Medica 2010, November 17th - 20th, Dusseldorf, Germany
visit site |
| |
 | October 19-22, 2010
We have successfully participated in GISE 2010, on the National Congress of the Italian Society of Invasive Cardiology, Genoa, Italy
visit site |
| |
 | October 2-6, 2010
We have successfully participated in CIRSE 2010, October 2nd - 6th, Feria Muestrario Internacional de Valencia, Av. de las Ferias, Valencia, Spain
visit site |
| |
 | September 21-25, 2010
We have successfully participated in TCT Conference 2010, September 21st - 25th, Washington Convention Center, Washington, DC, U.S.A.
visit site |
| |
 | July 22-24, 2010
Visit us at the XXXII SBHCI Congress, July 22-24th, Minas Gerais Brazil.
visit site |
| |
 | The new SES from Rontis gives to the physician the ability to confidently treat even the most difficult case.
The ABRAX Drug Eluting Stent releases sirolimus in coronary arteries. ABRAX uses a bio-degradable carrier polymer that ensures a more uniform release of the active drug from the surface of the stentOpen cell design of the ABRAX DES stent ensures balance of strength and flexibility and helps achieve greater vessel wall integrity surrounding the stent. The ABRAX stent comes pre-mounted on RONTIS' proven balloon catheter - the EUROPA Ultra. When crimped on the semi-compliant PTCA balloon catheter platform, the ABRAX DES system with its low tip entry profile and low crimp profile can be successfully used with confidence, for direct stenting in even the most difficult lesions.
With a wide range of stent lengths (10-34mm) & balloon diameters (2.00-4.00mm), RBPs from 14 to 16 bar and its innovative bio-degradable polymer, Abrax is an excellent choice for lesions in need for a drug-eluting stent. |
| |
 | Rontis announces the launch of the new Europa Ultra NC, non-compliant balloon dilatation catheter
Europa Ultra NC Rx PTCA 0.014" balloon dilatation catheter. The Europa Ultra NC has a 0.016" entry profile and a 0.021" crossing profile.
It may be used for post dilatation and has been designed to assist physicians who require noncompliant, high pressure pre and post dilatation performance for the treatment of a steadily growing population of patients with resistant and unyielding, pre and post dilatation performance.
It may achieve high pressure, while maintaining its flexibility. Rontis short & soft tapered tip ensures the unobstructed crossing of the most difficult lesions.
The product will be produced from 2.00 to 4.00 mm and balloon lengths from 10 to 30 mm.
The product is expected to receive a CE mark in October 2010. |
| |
 | July 21-24, 2010
We have successfully participated in ECIO 2010 Congress in Florence, Italy, 21-24 July
visit site |
| |
 | June 8-11, 2010
We have successfully participated in 12th National Congress of Cardiovascular Update, 8-11 June, 2010, Razi Conferences Hall, Tehran-Iran, Booth A1.
visit site |
| |
 | Rontis announces launch of the new Cronus HP, high-pressure balloon dilatation catheter
Cronus HP PTA OTW 0.035" balloon dilatation catheter achieves high pressures of up to 24 bar, while maintaining its flexibility and the compliance of a normal balloon. Rontis short & soft tapered tip ensures the unobstructed crossing of the most difficult lesions. The product will be produces at two different catheter active lengths (80 and 120cm), balloon diameters from 3 to 8 mm and balloon lengths from 20 to 40 mm. The product is expected to receive a CE mark in July 2010. |
| |
 | Rontis announces the launch of the new Cronus NV, balloon dilatation catheter for non-vascular applications
Cronus NV PTA OTW 0.035" balloon dilatation catheter achieves pressures of up to 17 bar, giving solutions to a variety of cases, such as in the bile duct. A wide range of balloon diameters (4-10mm) and lengths (20-80mm) is available. The HiFlow hydrophilic coating and its low profile make the Cronus NV the choice for non-vascular applications. The product is expected to receive a CE mark in July 2010. |
| |
| Rontis announces the launch of the new Europa Ultra CTO Balloon Dilatation Catheter at 1.25 and 1.50 mm.
Being an optimal choice for CTO lesions, the product will achieve very low primary and secondary profiles.
A new 0.016'', short, tapered, a-traumatic tip will ensure superb deliverability, while the laser-bonding at critical flex point will balance trackability and flexibility. Rontis own proprietary hydrophilic coating is the key for a smooth navigation through even the most challenging and tortuous coronary anatomy.
The product is expected to receive a CE mark in May 2010. |
| |
| January 25-28, 2010
We have successfully participated in the Arab Health Congress, which was held in Dubai, United Arab Emirates, from the 25th to the 28th of January 2010.
visit site |
| |
 | June 10, 2009
We have successfully participated for the 2nd time in the Sociedad Latinoamericana de Cardiologia Intervencionista (Solaci) Congress, which was held in Rio de Janeiro, Brazil, from the 10th to the 12th of June 2009.
visit site |
| |
 | May 19, 2009
We have successfully participated for the 7th consecutive time in the Euro PCR, which was held in Barcelona, Spain, from the 19th to the 22nd of May 2009.
visit site |
